Excellent analysis. Right so we are going to have the Germans having to start their no strings attached 12 month free obligation by 1 Nov 2018 which gives them “potentially” to the 1 Nov 2019 with absolute no revenue and no cost to resapp either. So is this management trying to say that the Germans could essentially be using an FDA approved device / test for 12 months free of charge? FDA will be around or before nov this year by the time the datas done and the submission is made I assume? Albeit the contract is exclusive only for 6 months. But still. Far out. Creating value for shareholders for sure.
RAP Price at posting:
14.5¢ Sentiment: Sell Disclosure: Not Held
